Association of circulating markers with cognitive decline after radiation therapy for brain metastasis.
Huntoon K, Anderson S, Ballman K, Twohy E, Dooley K, Jiang W, An Y, Li J, von Roemeling C, Qie Y, Ross O, Cerhan J, Whitton A, Greenspoon J, Parney I, Ashman J, Bahary J, Hadjipanayis C, Urbanic J, Farace E, Khuntia D, Laack N, Brown P, Roberge D, Kim B. Association of circulating markers with cognitive decline after radiation therapy for brain metastasis. Neuro-Oncology 2022, 25: 1123-1131. PMID: 36472389, PMCID: PMC10237411, DOI: 10.1093/neuonc/noac262.Peer-Reviewed Original ResearchConceptsWhole-brain radiation therapyStereotactic radiosurgeryBrain metastasesRadiation therapyNeurocognitive declineSerum levelsRadiation-induced neurocognitive declinePretreatment serum markersLow serum levelsAssociated with neurocognitive impairmentRandomized clinical trialsEnzyme-linked immunosorbent assaySurgical resectionSecondary endpointsSerum markersRetrospective analysisClinical trialsNeurocognitive impairmentCognitive impairmentMetastasisBlood samplesImmunosorbent assayMonthsSecondary analysisTherapy